Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LNP based nucleic acid therapeutics

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: $600.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration March 15, 2021

            Details:

            Takeda will have access to Genevant’s innovative LNP technology to develop nucleic acid therapeutics directed to specified targets in historically inaccessible hepatic stellate cells to treat liver fibrosis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): EDP-721

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: EDP-721

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2021

            Details:

            Enanta Pharmaceuticals announces New Oral Hbv Rna Destabilizer, EDP-721, as an additional component toward functional HBV Cure; expects to initiate phase 1 study mid-2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Takeda Pharmaceutical

            Deal Size: $470.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration December 10, 2020

            Details:

            HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda’s discovery portfolio.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SRT-015

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: SRT-015

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            The presentations demonstrate superior pharmacological properties of SRT-015 compared to other ASK1 inhibitors, including selonsertib, and provide potential explanations for the failure of selonsertib in clinical trials.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TXR-611

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TXR-611

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            In vivo efficacy with TXR-611 and 612 was evaluated using STAM™ mouse model where hits showed good tolerability and significant decrease in liver weight, steatosis, ballooning, fibrillar collagen deposition, NAFLD activity score and efficacy compares favorably to telmisartan.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydroxyl dendrimer

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            Details:

            Ashvattha has developed a novel hepatocyte targeted hydroxyl dendrimer therapeutic which enables selective targeting of farnesoid X receptor agonists on hepatocytes through the asialoglycoprotein receptor mediated uptake after systemic administration.